RxDoctor Payments DataLook up a doctor →

Philip Brodak, MD

Urology · Murrieta, CANPI 1417057514

Payments from drug & device makers

$731,412in general payments, 2019–2025

Across 509 payments — averaging $1436.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring International Pharmascience Center US$376K
  • Sumitomo Pharma America, Inc.$164K
  • Ferring Pharmaceuticals AS$126K
  • Neotract Inc.$19K
  • Arrow International, Inc.$14K
  • Teleflex LLC$11K
  • plus $22K from 53 others
$33,569in research payments, 2019–2025

Across 2 payments — averaging $16,784 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Seikagaku Corporation$34K

What the payments were for

  • Consulting fees$7,28037%
  • Travel & lodging$6243%
  • Food & beverage$11,16256%
  • Education$6603%
  • Gifts$750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ferring International Pharmascience Center US8$375,782
Sumitomo Pharma America, Inc.29$164,290
Ferring Pharmaceuticals AS5$125,912
Neotract Inc.12$18,959
Arrow International, Inc.5$13,799
Teleflex LLC15$10,793
Bayer20$5,560
Astellas Pharma US Inc30$3,223
Teleflex Medical Incorporated1$3,037
Coloplast16$1,121
Dendreon Pharmaceuticals LLC37$1,108
Procept Biorobotics Corporation15$872
AbbVie(2 entities)45$869
Johnson & Johnson28$705
Antares Pharma, Inc.50$581
Pfizer41$443
Endo USA, Inc.15$426
Boston Scientific9$342
Myriad Genetic Laboratories, Inc.9$322
Urogen Pharma, Inc.11$321
Laborie Medical Technologies Corp.3$239
Verity Pharmaceuticals Inc.9$208
Accord Healthcare, Inc.5$206
Medtronic(2 entities)2$195
Endo Pharmaceuticals Inc.9$191
Caldera Medical, Inc2$185
C. R. Bard, Inc. & Subsidiaries5$163
Amgen3$134
Ferring Pharmaceuticals Inc.5$114
Halozyme Inc6$111
Axonics, Inc.5$108
AstraZeneca5$99
Intuitive Surgical1$91
Myovant Sciences Inc.4$77
Sun Pharmaceutical Industries Inc.4$73
Biotissue Holdings Inc.3$69
Davol Inc.2$57
Merck2$54
Duchesnay USA Incorporated3$51
Immunitybio, Inc.3$50
Zyla Life Sciences, Inc.4$47
Alnylam Pharmaceuticals Inc.2$40
Blue Earth Diagnostics1$38
Novartis2$38
AMAG Pharmaceuticals, Inc.2$38
Olympus America Inc.2$37
Foundation Medicine, Inc.2$29
Progenics Pharmaceuticals, Inc.1$24
Smith+Nephew1$24
Baxter Healthcare1$21
BD1$20
Aytu Biopharma, Inc.1$18
Palette Life Sciences, Inc.1$17
Dentsply IH Inc.1$16
Telix Pharmaceuticals1$15
ABC Home Medical Supply, Inc.1$14
Therapeuticsmd, Inc.1$13
Integra Lifesciences Corporation1$13
BK Medical Holding Company Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$731,412 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$747,726
Medicare patients
1,452
Services billed
24,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide17$237,952
Lupron DepotLeuprolide Acetate12$140,147
XgevaDenosumab42$127,073
GemtesaVibegron112$121,432
OrgovyxRelugolix45$118,467
MyrbetriqMirabegron127$118,249
ElmironPentosan Polysulfate Sodium25$47,873
XyostedTestosterone Enanthate18$26,712
Testosterone Cypionate388$21,853
Potassium Citrate ErPotassium Citrate125$19,661
Testosterone68$17,950
Mirabegron ErMirabegron18$12,490
Tamsulosin Hcl584$11,809
BotoxOnabotulinumtoxina11$9,539
Oxybutynin Chloride ErOxybutynin Chloride241$8,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$164,290$239,899157 claims
BayerNubeqa$5,560$237,95217 claims
AbbVieLupron Depot, Botox, Armour Thyroid$869$151,31045 claims
AmgenXgeva$134$127,07342 claims
Astellas Pharma US IncMyrbetriq$3,223$118,249127 claims
Antares Pharma, Inc.Xyosted$581$26,71218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.

Other urology in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →